IMUGENE LIMITED — Board/Management Information 2024

Nov 14, 2024

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

Retirement of Jens Eckstein as Non-Executive Director

SYDNEY, Australia, 15 November 2024: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, announces that further to today's Annual General Meeting (AGM), Jens Eckstein has resigned from his position as a Non-Executive Director of Imugene to focus on his other business interests.

Jens has been a valued member of Imugene's Board since May 2019, providing extensive insights and guidance to the Company.

Imugene’s Executive Chairman, Paul Hopper, commented: “I extend my gratitude to Jens for his support and dedication throughout his time with Imugene, and I wish him great success in his future ventures and pursuits."

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer

info@imugene.com

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited Follow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and

novel immunotherapies that seek to activate the immune system of cancer patients to

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.

IMUGENE LIMITED ACN 009 179 551

2